2020 Position Statement on Off-Label Use and Misuse of Testosterone, Growth Hormone, Thyroid Hormone, and Adrenal Supplements: Risks and Costs of a Growing Problem

Resumen documental de ASEM

Official American Association of Clinical Endocrinology document (2020) on “2020 Position Statement on Off-Label Use and Misuse of Testosterone, Growth Hormone, Thyroid Hormone, and Adrenal Supplements: Risks and Costs of a Growing Problem”. This position statement raises awareness about the risks of off-label use and misuse of testosterone, growth hormone, thyroid hormone, and adrenal supplements. This statement distinguishes off-label hormone use from legitimate use for diagnoses such as male hypogonadism, growth hormone deficiency, hypothyroidism, and adrenal insufficiency. DOI: 10.4158/PS-2019-0540.

Este resumen facilita la identificación del documento. Para consultar recomendaciones clínicas, consulte siempre la versión oficial vigente y su fecha de actualización.